When Healthcare Meets High-Stakes Regulation
Building a tech startup is hard. Building one in healthcare? That's a different game entirely — and BioticsAI CEO Robhy Bustami is living proof of what it takes to navigate that gauntlet.
Bustami recently joined host Isabelle Johannessen on the Build Mode podcast, where the two dug into what it actually looks like to build a company in one of the most regulated industries on the planet. From chasing FDA approval to keeping a team energized in the face of endless bureaucratic hurdles, Bustami's account is a revealing look at the grit required to push healthcare innovation forward.
The FDA Approval Grind
For any company developing medical technology or AI-powered health tools in the United States, the FDA isn't a finish line — it's a marathon with no clear mile markers. The approval process can stretch years, demand rounds of clinical validation, and shift in requirements as regulators work to keep pace with rapidly evolving technologies.
For founders like Bustami, that uncertainty isn't just a legal challenge. It shapes every business decision, from how much runway you raise to how you communicate timelines to investors and early customers. Getting the science right is one thing; getting the regulatory story right is another skill set entirely.
The pressure is especially acute for AI-driven health companies. Regulators are still developing frameworks for how machine learning tools fit into existing approval pathways — which means founders are often building the playbook as they go, navigating ambiguity without a clear precedent to follow.
Fundraising in a Regulated Space
Venture capital loves a fast-moving market, but healthcare moves at the speed of compliance. That tension makes fundraising for regulated health startups a uniquely demanding exercise.
Investors need to believe not just in the technology, but in the team's ability to survive the regulatory marathon without burning through capital. Bustami's experience navigating that conversation — explaining FDA timelines, justifying compliance costs, and maintaining investor confidence during the slow periods — speaks to a challenge many health tech founders quietly struggle with.
The reward, of course, is that companies which clear those hurdles earn a defensible moat. FDA approval isn't just a regulatory checkbox; it's a competitive advantage that's genuinely hard to replicate.
Keeping the Team Motivated
Perhaps the most underappreciated challenge Bustami touched on is the human one: how do you keep a team fired up when progress feels slow and the finish line keeps moving?
In high-growth tech startups, momentum itself is a motivator. In healthcare, you're often asking people to grind through years of validation work before seeing any market traction. The companies that make it are usually the ones where leadership has found a way to celebrate incremental wins — a successful trial phase, a positive pre-submission meeting with regulators — and keep the mission front and center.
Why It Matters
Healthcare AI is one of the most consequential frontiers in technology right now. The companies working through these regulatory challenges aren't just chasing valuations — they're building tools that could meaningfully improve patient outcomes and reshape how medicine is practiced.
Bustami's conversation on Build Mode is a valuable reminder that the path from idea to approved healthcare product is long, expensive, and unglamorous. But for the founders willing to do the work, the opportunity is enormous.
Source: TechCrunch / Build Mode podcast featuring BioticsAI CEO Robhy Bustami and host Isabelle Johannessen.
